Pediatric transplantation · 2026
Donor-Derived Cell-Free DNA in Stable Pediatric Kidney Transplant Recipients: Influence of Donor Obesity and Recipient Size.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Steinke Julia, Harshman Lyndsay, Kirshner Kelly, Kale Arundhati, Winnicki Erica, Ranch Daniel, Chandar Jayanthi, Pizzo Helen, Kaur Arshdeep, Hanson Paul, Chen Zunqiu, Shen Ling, Puliyanda Dechu
Аннотация
BACKGROUND: Donor-derived cell-free DNA (dd-cfDNA) is increasingly used as a noninvasive marker of kidney allograft injury, but adult-derived cutoffs may not be applicable to pediatric recipients, particularly in the setting of donor-recipient size mismatch. We evaluated dd-cfDNA levels in stable pediatric kidney transplant (KT) recipients and assessed variation by recipient weight and donor body mass index (BMI).
METHODS: Retrospective data were collected from seven U.S. pediatric KT centers. Clinically stable recipients < 18 years of age (no de novo donor specific antibody, biopsy-proven rejection or BK viremia/nephropathy), with ≥ 2 dd-cfDNA measurements per year were included. Recipients were stratified by weight at dd-cfDNA collection (< 20 kg, 20-50 kg, > 50 kg). Donor BMI was categorized as underweight (≤ 18.5), normal (18.6-24.9), overweight (25-29.9), or obese (≥ 30). Comparisons were performed using linear mixed-effects models.
RESULTS: Among 178 recipients, mean dd-cfDNA did not differ by recipient weight (< 20 kg: 0.51 ± 0.44; 20-50 kg: 0.65 ± 1.28; > 50 kg: 0.49 ± 0.70). Median dd-cfDNA was similar across donor BMI categories. However, among obese donors, recipients < 20 kg had 1.3-fold higher dd-cfDNA (p = 0.044). Donor-recipient body surface area mismatch > 1.5 was associated with 1.083-fold higher dd-cfDNA up to 5 years post-transplant (p = 0.016).
CONCLUSIONS: In stable pediatric KT recipients, dd-cfDNA levels were well below the adult-derived 1% cutoff, reinforcing the generalizability of this cutoff to the pediatric population. Recipients < 20 kg with donor BMI > 30 kg/m2 or in the setting of a donor-recipient BSA mismatch > 1.5 were associated with higher dd-cfDNA levels.
METHODS: Retrospective data were collected from seven U.S. pediatric KT centers. Clinically stable recipients < 18 years of age (no de novo donor specific antibody, biopsy-proven rejection or BK viremia/nephropathy), with ≥ 2 dd-cfDNA measurements per year were included. Recipients were stratified by weight at dd-cfDNA collection (< 20 kg, 20-50 kg, > 50 kg). Donor BMI was categorized as underweight (≤ 18.5), normal (18.6-24.9), overweight (25-29.9), or obese (≥ 30). Comparisons were performed using linear mixed-effects models.
RESULTS: Among 178 recipients, mean dd-cfDNA did not differ by recipient weight (< 20 kg: 0.51 ± 0.44; 20-50 kg: 0.65 ± 1.28; > 50 kg: 0.49 ± 0.70). Median dd-cfDNA was similar across donor BMI categories. However, among obese donors, recipients < 20 kg had 1.3-fold higher dd-cfDNA (p = 0.044). Donor-recipient body surface area mismatch > 1.5 was associated with 1.083-fold higher dd-cfDNA up to 5 years post-transplant (p = 0.016).
CONCLUSIONS: In stable pediatric KT recipients, dd-cfDNA levels were well below the adult-derived 1% cutoff, reinforcing the generalizability of this cutoff to the pediatric population. Recipients < 20 kg with donor BMI > 30 kg/m2 or in the setting of a donor-recipient BSA mismatch > 1.5 were associated with higher dd-cfDNA levels.